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Abstract
In this study of 17 patients with chronic active hepatitis B, the loss of hepatitis B virus DNA, the return to normal of alanine aminotransferase activities, and histological improvement after six months' treatment with 3 million units three times weekly with interferon alfa-2b, was 
Results
At the end of treatment, similar percentages of HBeAg positive/anti-HBe negative patients and HBeAg negative/anti-HBe positive patients had achieved negative HBV-DNA, normal ALT, and histological improvement (4000 and 41.7%, respectively), but there were more patients who had less than a 50% reduction in HBV-DNA and ALT and no change in liver histology in the latter group (Fig 1) O HBV-DNA negative, normalALT, histological improvement I HBV-DNA andALT reduced by at least 50%, with minor improvement in liver histology * HBV-DNA andALT reduced by less than 50% and no change in liver histology positive patients sustained the negative HBV DNA, normal ALT, and histological improvement, compared with 8-3% of the HBeAg negative cases (Fig 2) . Influenza like symptoms occurred in 70 5% of patients and mild leukopenia in 29-4%. These side effects, however, did not necessitate withdrawal of treatment in any patients.
Conclusions
A beneficial response to six months' treatment with low doses of interferon alfa-2b was achieved in 40-41-7% of patients with either the 'wild type' virus (HBeAg positive/anti-HBe negative) or the mutant virus (HBeAg negative/anti-HBe positive). Although the reappearance of HBV-DNA was seen in most of those who had responded when treatment was stopped, a higher percentage of HBeAg positive patients had a sustained loss of HBV-DNA, return to normal of ALT, and histological improvement response (20%) compared with HBeAg negative patients (8-3%).
Treatment with interferon alfa-2b requires further investigation and the value of long term interferon treatment for patients in whom disease activity is only temporarily controlled during treatment should be reconsidered.
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